Nordic Star 2025 Pitch Competition 1
Pitch session 1 out of 2. SME finalists will give four-minute pitches of their companies in front of the pitch competition jury and the conference audience.
NLSDays Nordic Star is a pitch competition for Nordic life science SMEs. A selection of high-potential Nordic SMEs compete for the Nordic Star Award during each NLSDays conference.
Pitching Companies:
AAX Biotech AB 🇸🇪
AAX Biotech has developed a new superior antibody format solving unmet needs in the bispecifics/multispecific antibody field and advanced cell therapies such as CAR-T, improving developability and enabling development of next-generation therapeutics.
Acorai 🇸🇪
Acorai is a non-invasive diagnostic medical device combining multi-sensor hardware (seismic, acoustic, optical, electrical) with machine learning algorithms to measure cardiac and pulmonary pressures. The solution is used in acute, in-hospital, and community care settings for the detection and management of heart failure.
Aqilion AB 🇸🇪
Aqilion is developing oral small molecule therapies designed to reshape immune signaling in chronic inflammatory diseases.
Dermeco Oy 🇫🇮
Dermeco Oy has developed the world’s first and only biodegradable hydrocolloid wound dressing that can be applied to blisters and minor wounds, surgical wounds, as well as patches supporting acne treatment.
Fepod Oy Ltd 🇫🇮
Fepod is a healthtech company developing next-generation point-of-care diagnostics for substance detection — starting with alcohols. Their platform is designed to deliver rapid, precise, and actionable results in prehospital, clinical, and occupational settings.
Inverna Therapeutics 🇩🇰
Inverna’s unique approach to pseudo-exon activation enables unprecedented versatility and specificity. With their proprietary drug discovery platform, they can rapidly design, test and develop highly selective activators, due to their specific designs toward unique sequence elements controlling pseudo-exon repression levels.
KLYV Therapeutics AS 🇳🇴
Klyv Therapeutics is a Norwegian biotech start-up developing first-in-class therapies for fibrotic disease. Their lead program targets ADAMTS4, a novel extracellular enzyme that drives fibrosis and progression of heart failure with preserved ejection fraction (HFpEF).